Mike Mason, SVP and President, Lilly Diabetes (Lilly)
Eli Lilly ends Q1 on a high note on the heels of positive obesity trial data
It was all about tirzepatide for Eli Lilly this morning. And in the immediate aftermath of a Phase III readout, analysts wanted to know what …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
